Paratek Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
PRTK Paratek Pharmaceuticals Inc
EGRAY Energy Resources Of Australia Ltd
IVAC Intevac Inc
AMPX Amprius Technologies Inc
PFE Pfizer Inc
BNOX Bionomics Ltd
CRKN Crown Electrokinetics Corp.
YMAB Y-mAbs Therapeutics Inc
VINE Fresh Vine Wine Inc

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The Company's lead product, NUZYRA (omadacycline), is an oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI), caused by susceptible pathogens. Omadacycline is used in the emergency room, hospital, and community care settings. Its second product, SEYSARA (Sarecycline), is an oral therapy for the treatment of moderate to severe acne vulgaris.

Closing Price
Day's Change
0.42 (19.81%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

S&P Global Ratings upgrades Macy's to BB-plus after solid operating results for Q3

6:34 am ET November 18, 2022 (MarketWatch)

S&P Global Ratings upgraded its rating on Macy's Inc. to BB-plus from BB, and said the department store chain continues to deliver solid operating results and deleverage despite the challenging environment for the retail sector. The new rating is just one notch below investment grade and the outlook is stable. "Macy's has made material progress toward improving liquidity and operating performance while maintaining credit metrics well below our upside leverage threshold of 3x, even in this volatile year for apparel and department store companies," the rating agency said in a statement. Macy's on Thursday posted better-than-expected third-quarter earnings and raised its full-year guidance. Like other retailers, Macy's said it saw a sudden dip in sales mid-October that continued into November and said it now expects holiday spending to start later than usual. Shares were up 1% premarket Friday and are down 13.4% in the year to date, while the S&P 500 has fallen 17%.

-Ciara Linnane


(END) Dow Jones Newswires

November 18, 2022 06:34 ET (11:34 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.